drugset / Trial / NCT06356389
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
Phase 1/2
Completed
60 enrolled
Zhejiang Jingxin Pharmaceutical Co., Ltd.
Shanghai Mental Health Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled, dose-increasing phase Ib/II clinical trial to evaluate the safety, tolerance and pharmacokinetic characteristics of JX11502MA capsules administered multiple times in patients with schizophrenia
Timeline
- Start
- 2022-03-02
- Primary completion
- 2022-12-27
- Completion
- 2023-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JX11502MA | Unknown | 1.5 mg | Oral |
| Subject | JX11502MA | Unknown | 3 mg | Oral |
| Subject | JX11502MA | Unknown | 6 mg | Oral |